Chen Lichtenstein - Jun 5, 2025 Form 4 Insider Report for TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA)

Role
Director
Signature
/s/ Dov Bergwerk as attorney-in-fact for Chen Lichtenstein
Stock symbol
TEVA
Transactions as of
Jun 5, 2025
Transactions value $
$0
Form type
4
Date filed
6/9/2025, 04:07 PM
Previous filing
Dec 4, 2024
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Lichtenstein Chen Director C/O TEVA PHARMACEUTICAL INDUSTRIES LTD., 124 DVORA HANEVI'A ST.,, TEL AVIV, ISRAEL /s/ Dov Bergwerk as attorney-in-fact for Chen Lichtenstein 2025-06-09 0002046465

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction TEVA Restricted Share Units Award $0 +14.5K $0.00 14.5K Jun 5, 2025 Ordinary Shares 14.5K Direct F1, F2, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.
F2 Restricted share units were granted on June 5, 2025 and vest on June 5, 2026.
F3 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.